U.S. PRODUCERS'/TABLETERS' QUESTIONNAIRE

CHLORINATED ISOCYANURATES FROM CHINA AND SPAIN

This questionnaire must be received by the Commission by <u>July 8, 2022</u>

See last page for filing instructions.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its review of the antidumping duty orders concerning chlorinated isocyanurates ("chlorinated isos") from China and Spain (Inv. Nos. 731-TA-1082-1083 (Third Review)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your firm's possession (19 U.S.C. § 1333(a)).

Name of firm

City	State	Zip Code
Website _		
Has your fir	n produced chlorinated isos (as defined on the next page	at any time since January 1, 2016?
☐ NO	(Sign the certification below and promptly return only this p	age of the questionnaire to the Commission)
YES	(Complete all parts of the questionnaire, and return the enti	re questionnaire to the Commission)
•	stionnaire via the Commission <i>Drop Box</i> by clicking bbox.usitc.gov/oinv/ (PIN: ISOS)	on the following link:
	CERTIFICATION	
e and belief this certific on provided	mation herein supplied in response to this question and understand that the information submitted is subjection tion I also grant consent for the Commission, and i this questionnaire and throughout this proceeding in	ect to audit and verification by the Com ts employees and contract personnel,
e and belief this certifice on provided by the Come dersigned, ac g or other p (a) for deve and evaluati 3; or (ii) by U	mation herein supplied in response to this question and understand that the information submitted is subjection I also grant consent for the Commission, and in this questionnaire and throughout this proceeding insision on the same or similar merchandise. Inowledge that information submitted in response to occeedings may be disclosed to and used: (i) by the Comping or maintaining the records of this or a related plans relating to the programs, personnel, and operations.	ect to audit and verification by the Come ts employees and contract personnel, in any other import-injury proceedings this request for information and thro mmission, its employees and Offices, a roceeding, or (b) in internal investigations of the Commission including und
e and belief this certifice on provided by the Come dersigned, ac g or other p (a) for deve and evaluati 3; or (ii) by U	mation herein supplied in response to this question and understand that the information submitted is subjection I also grant consent for the Commission, and in this questionnaire and throughout this proceeding insision on the same or similar merchandise. Inowledge that information submitted in response to occeedings may be disclosed to and used: (i) by the Cooping or maintaining the records of this or a related pass relating to the programs, personnel, and operation	ect to audit and verification by the Come ts employees and contract personnel, in any other import-injury proceedings this request for information and thro mmission, its employees and Offices, a roceeding, or (b) in internal investigations of the Commission including und
e and belief this certifice on provided by the Come dersigned, ac g or other p (a) for deve and evaluati 3; or (ii) by U	emation herein supplied in response to this question and understand that the information submitted is subjection I also grant consent for the Commission, and in this questionnaire and throughout this proceeding in this questionnaire and throughout this proceeding insission on the same or similar merchandise. Showledge that information submitted in response to proceedings may be disclosed to and used: (i) by the Comping or maintaining the records of this or a related plans relating to the programs, personnel, and operated. So, government employees and contract personnel, solesign appropriate nondisclosure agreements.	ect to audit and verification by the Come ts employees and contract personnel, in any other import-injury proceedings this request for information and thro mmission, its employees and Offices, a roceeding, or (b) in internal investigations of the Commission including und

PART I.—GENERAL INFORMATION

Background.--On June 24, 2005, the Department of Commerce ("Commerce") issued antidumping duty orders on imports of chlorinated isos from China and Spain. On October 1, 2021, the Commission instituted a review pursuant to section 751(c) of the Tariff Act of 1930 (19 U.S.C. § 1675(c)) (the Act) to determine whether revocation of the orders would be likely to lead to continuation or recurrence of material injury to the domestic industry within a reasonably foreseeable time. If both the Commission and Commerce make an affirmative determination, the order will remain in place. If either the Commission or Commerce makes a negative determination, Commerce will revoke the order. Questionnaires and other information pertinent to this proceeding are available at https://usitc.gov/investigations/701731/2021/chlorinated isocyanurates china and spain/third revie w full.htm.

<u>Chlorinated isos</u> covered by these investigations are derivatives of cyanuric acid, described as chlorinated s-triazine triones. There are three primary chemical compositions of chlorinated isos: (1) trichloroisocyanuric acid (Cl₃(NCO)₃); (2) sodium dichloroisocyanurate (dehydrate) (NaCl₂ (NCO)₃(2H₂O); and (3) sodium dichloroisocyanurate (anhydrous) (NaCl₂(NCO)₃). The AD Orders cover all chlorinated isos.

Chlorinated isos are currently imported under statistical reporting numbers 2933.69.6015, 2933.69.6021, and 2933.69.6050 of the Harmonized Tariff Schedule of the United States (HTSUS). Chlorinated isos may also be imported under HTS subheadings 3808.59.40, 3808.59.50, and 3808.94.50. The HTSUS provisions are for convenience and customs purposes; the written description of the scope is dispositive.

<u>Reporting of information</u>.--If information is not readily available from your records in exactly the form requested, furnish carefully prepared estimates. If your firm is completing more than one questionnaire in connection with this proceeding (i.e., a producer, importer, and/or purchaser questionnaire), you need not respond to duplicated questions in the questionnaires.

<u>Confidentiality</u>.--The commercial and financial data furnished in response to this questionnaire that reveal the individual operations of your firm will be treated as confidential by the Commission to the extent that such data are not otherwise available to the public and will not be disclosed except as may be required by law (see 19 U.S.C. § 1677f). Such confidential information will not be published in a manner that will reveal the individual operations of your firm; however, general characterizations of numerical business proprietary information (such as discussion of trends) will be treated as confidential business information only at the request of the submitter for good cause shown.

<u>Verification</u>.--The information submitted in this questionnaire is subject to audit and verification by the Commission. To facilitate possible verification of data, please keep all of your files, worksheets, and supporting documents used in the preparation of the questionnaire response. Please also retain a copy of the final document that you submit.

<u>Release of information</u>.--The information provided by your firm in response to this questionnaire, as well as any other business proprietary information submitted by your firm to the Commission in connection with this proceeding, may become subject to, and released under, the administrative

¹ The tariff classification 2933.69.6015 covers sodium cichloroisocyanurates (anhydrous and dehydrate forms) and trichloroisocyanuric acid. The tariff classifications 2933.69.6021 and 2933.69.6050 represent basket categories that include chlorinated isos and other compounds including unfused triazine rings.

protective order provisions of the Tariff Act of 1930 (19 U.S.C. § 1677f) and section 207.7 of the Commission's Rules of Practice and Procedure (19 CFR § 207.7). This means that certain lawyers and other authorized individuals may temporarily be given access to the information for use in connection with this proceeding or other import-injury proceedings conducted by the Commission on the same or similar merchandise; those individuals would be subject to severe penalties if the information were divulged to unauthorized individuals.

<u>D-GRIDS tool.</u>--The Commission has a tool that firms can use to move data from their own MS Excel compilation files into self-contained data tables within this MS Word questionnaire, thereby reducing the amount of cell-by-cell data entry that would be required to complete this form. This tool is a macroenabled MS Excel file available for download from the Commission's generic questionnaires webpage (https://www.usitc.gov/trade_remedy/question.htm) called the "D-GRIDs tool." Use of this tool to help your firm complete this questionnaire is *optional*. Firms opting to use the D-GRIDs tool to populate their data into this questionnaire will need the D-GRIDs specification sheet PDF file specific to this proceeding (available on the case page which is linked under the "Background" above) which includes the necessary references relating to this questionnaire, as well as the macro-enable MS Excel D-GRIDs tool itself from the generic questionnaires page. More detailed instructions on how to use the D-GRIDs tool are available within the D-GRIDs tool itself.

I-1. <u>OMB statistics</u>.--Please report below the actual number of hours required and the cost to your firm of completing this questionnaire.

Hours	Dollars

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response, including the time for reviewing instructions, gathering data, and completing and reviewing the questionnaire.

We welcome comments regarding the accuracy of this burden estimate, suggestions for reducing the burden, and any suggestions for improving this questionnaire. Please attach such comments to your response or send to the Office of Investigations, USITC, 500 E St. SW, Washington, DC 20436.

I-2a. <u>Establishments covered</u>.--Provide the city, state, zip code, and brief description of each establishment covered by this questionnaire. Firms operating more than one establishment should combine the data for all establishments into a single report.

"<u>Establishment</u>"--Each facility of a firm involved in the <u>production</u> of chlorinated isos, including auxiliary facilities operated in conjunction with (whether or not physically separate from) such facilities.

Establishments Covered ¹	City, State	Zip (5 digit)	Description
1			
2			
3			
4			
5			
6			
¹ Additional discu	ussion on establishments con	solidated in this question	onnaire:

I-2b.	<u>Stock symbol information.</u> If your firm or parent firm is publicly traded, please specify the stock exchange and trading symbol:			
I-2c.	-	<u>External counsel.</u> — If your firm or parent firm is represented by external counsel in relation to this proceeding, please specify the name of the law firm and the lead attorney(s).		
	Law firm:			
	Lead attorney(s):			

I-3. <u>Position regarding continuation of order.</u>—Does your firm support or oppose continuation of the following antidumping duty orders currently in place for chlorinated isos?

Country	Order type	Support	Oppose	Take no position
China	Antidumping duty			
Spain	Antidumping duty			

S. Producers' Questionnaire	 Chlorinated Isos (Third Review 	Page 5		
. OwnershipIs your fi	rm owned, in whole or in part, by	any other firm?		
☐ No ☐ Ye	No YesList the following information, relating to the ultimate parent/owner.			
Firm name	Country	Extent of ownership (percent)		
foreign, that are engage engaged in exporting of "Related firm" —A firm a firm that solely or joint that was solely or joint	ged in importing chlorinated isos is chlorinated isos to the United State of that your firm solely or jointly over intly owned, managed, or otherw	tes? wned, managed, or otherwise controlled; ise controlled your firm; and/or a firm e controlled by a firm that also solely or		
☐ No ☐ Ye	sList the following information.			
Firm name	Country	Affiliation		

I-6.	Related producers. Does your firm have any related firms, either domestic or foreign, that are engaged in the production of chlorinated isos?				
	"Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.				
	No YesList the	No YesList the following information.			
	Firm name	Country	Affiliation		

PART II.--TRADE AND RELATED INFORMATION

Title Email Telephone

Further information on this part of the questionnaire can be obtained from Keysha Martinez (202-205-2136, Keysha.Martinez@usitc.gov). Supply all data requested on a calendar-year basis.

II-1.	Contact informationPlease identify the responsible individual and the manner by which			
	Commission sta in Part II.	off may contact that individual regarding the confidential information submitted		
	Name			

II-2a. <u>Changes in operations.</u>—Please indicate whether your firm has experienced any of the following changes in relation to the production of chlorinated isos since January 1, 2016.

Check as many as appropriate.		If checked, please describe the nature, date(s), and significance of any such reported changes as well as the business reasons for them; leave completely blank if not applicable
	Plant openings	
	Plant closings	
	Relocations	
	Expansions	
	Acquisitions	
	Consolidations	
	Prolonged shutdowns or production curtailments	
	Revised labor agreements	
	Other (e.g., technology)	

II-2b.	COVID-19 pandemic.—Since January 1, 2020, has the COVID-19 pandemic or have any
	government actions taken to contain the spread of the COVID-19 virus resulted in changes in
	your firm's supply chain arrangements, production, employment, and shipments relating to
	chlorinated isos? In your response, please discuss the duration and timing of any such changes
	as they relate to your firm's operations.

No	Yes	If yes, describe these changes including a separate discussion of the (a) supply chain impact, (b) production and shipments impact, and (c) employment impact of the COVID-19 pandemic.

II-2c. <u>Anticipated changes in operations.</u>—Does your firm anticipate any changes in in the character of its operations or organization relating to the production of chlorinated isos in the future?

No	Yes	If yes, supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentations that address this issue.

II-3a. **Production using same machinery.**-- Please report your firm's production of products made using the same equipment, machinery, or employees as used to produce chlorinated isos, and the combined production capacity on this shared equipment, machinery, or employees in the periods indicated.

"Overall production capacity" or "capacity" – The level of production that your establishment(s) could reasonably have expected to attain during the specified periods. Assume normal operating conditions (i.e., using equipment and machinery in place and ready to operate; normal operating levels (hours per week/weeks per year) and time for downtime, maintenance, repair, and cleanup).

Note.--If your firm does not produce any out-of-scope merchandise on the same machinery and equipment as scope merchandise then the "overall production capacity" numbers reported in this question should be exactly equal to the "average production capacity" numbers reported in question II-4. If, however, your firm does produce out-of-scope merchandise using the same machinery and equipment as scope merchandise, then the "average production capacity" reported in question II-4 should exclude the portion of "overall production capacity" that was used to produce this out-of-scope merchandise.

"**Production**" – All production in your U.S. establishment(s), including production consumed internally within your firm and production for another firm under a toll agreement.

Quantity (in short tons)							
	Calendar year			January-March			
Item	2019 2020 20		2021	2021	2022		
Overall production capacity ¹							
Production of:							
Chlorinated isos ²	0	0	0	0	0		
Other products ³							
Total production using same machinery or workers	0	0	0	0	0		

¹ Data reported for capacity (first line) should be greater than data reported for total production (last line).

² Data entered for production of chlorinated isos will populate here once reported in question II-4.

³ Please identify these products: .

115	Droducars'	Ouestionnaire -	Chlorinated	Isos (Third	Roviow
U.S.	Producers	Questionnaire –	· uniorinated	isos u nira	Review

Н	ours per v	week	Weeks p	er year		
			escribe the metho xplain any change			rall productior
	on constra		describe the con	straint(s) that s	et the limit(s)	on your firm's
Product s	hifting.—					
(i) Is	your firm		ch production (ca e equipment and/		n chlorinated	isos and other
(i) Is	your firm	If yes—(i.e	•	or labor? other products	or are able t	o produce oth
(i) Is	your firm roducts us	If yes—(i.e	e equipment and/	or labor? other products	or are able t	o produce oth

Integrated Producers' chlorinated isos operations

II-4. INTEGRATED Producers' chlorinated isos operations: Production, shipment, and inventory data.-Report your firm's production capacity, production, shipments, and inventories related to non-toll production of all granular/powder chlorinated isos in its U.S. establishment(s) and any tableting operations your firm conducts on its own internally produced granular/powder chlorinated isos, including tableting services pursuant to a toll arrangement, during the specified periods. Do not report any toll production that your firm performs for other firms in this question (report these data in question II-12 of the questionnaire).

"Average production capacity" or "capacity" – The level of production that your establishment(s) could reasonably have expected to attain during the specified periods. Assume normal operating conditions (i.e., using equipment and machinery in place and ready to operate; normal operating levels (hours per week/weeks per year) and time for downtime, maintenance, repair, and cleanup; and a typical or representative product mix).

"Production" – All production in your U.S. establishment(s), including production consumed internally within your firm and production for another firm under a toll agreement.

"Commercial U.S. shipments" –Shipments made within the United States as a result of an arm's length commercial transaction in the ordinary course of business. Report <u>net values</u> (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods) in U.S. dollars, f.o.b. your point of shipment.

"Internal consumption" – Product consumed internally by your firm. Such transactions are valued at fair market value.

"Transfers to related firms" – Shipments made to related firms. Such transactions are valued at fair market value.

"Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.

"Export shipments" – Shipments to destinations outside the United States, including shipments to related firms.

"Inventories" — Finished goods inventory, not raw materials or work-in-progress.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the trade data, as Commission staff may contact your firm regarding questions on the trade data. The Commission may also request that your company submit copies of the supporting documents/records (such as production and sales schedules, inventory records, etc.) used to compile these data.

II-4a. <u>INTEGRATED Producers' chlorinated isos operations: Production, shipment, and inventory data</u>.—*Continued.*

Note.--Please report your firm's integrated chlorinated isos operations, including all granular/powder chlorinated isos and any tableting operations performed on its own internally produced granular/powder chlorinated isos)

	Quantity (in sh	nort tons) and v	alue (<i>in \$1,000</i>)		
		Calendar year	r	January-	-March
Item	2019	2020	2021	2021	2022
Average production capacity ¹ (quantity) (A)					
Beginning-of-period inventories (quantity) (B)					
Production (quantity) (C)					
U.S. shipments: Commercial shipments: quantity (D)					
value (E)					
Internal consumption: ² quantity (F)					
value (G)					
Transfers to related firms: ² quantity (H)					
value (I)					
Export shipments: ³ quantity (J)					
value (K)					
End-of-period inventories (quantity) (L)					
¹ The production capacity report describe the methodology used to cadditional pages as necessary) ² Internal consumption and trandifferent basis for valuing these transtends data above at fair market value; ³ Identify your firm's principal expressions.	alculate product sfers to related f nsactions, please i.	ion capacity, and	l explain any chang ued at fair market	ges in reported capa value. Does your fi	rm use a

II-4a. <u>INTEGRATED Producers' chlorinated isos operations: Production, shipment, and inventory</u> data.--*Continued*

<u>RECONCILIATION OF SHIPMENTS, PRODUCTION, AND INVENTORY.</u>—Generally, the data reported for the end-of-period inventories (i.e., line L) should be equal to the beginning-of-period inventories (i.e., line B), plus production (i.e., line C), less total shipments (i.e., lines D, F, H, and J). Please ensure that any differences are not due to data entry errors in completing this form, but rather reflect your firm's actual records; and, also provide explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

		Calendar year	January-March			
Item	2019	2020	2021	2021	2022	
B+C-D-F-H-J-L = should equal zero ("0") or provide an explanation. ¹	0	0	0	0	0	
¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless accurate:						

II-4b. INTEGRATED Producers' chlorinated isos operations: Historical U.S. shipment data. --Report the quantity and value of your firm's U.S. shipments (including commercial U.S. shipments, internal consumption, and transfers, but <u>not</u> including exports) of chlorinated isos produced in your U.S. establishment(s) during the specified periods.

Quantity (in short tons)						
Item 2016 2017 2018						
U.S. shipments:						
Quantity						
Value						

II-5. <u>INTEGRATED Producers' chlorinated isos operations: Channels of distribution</u>.--Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) by channel of distribution.

Quantity (in short tons)						
	Calendar year			January-March		
Item	2019	2020	2021	2021	2022	
Channels of distribution: U.S. shipments— to distributors (M)						
to repackers/tableters (N)						
to retailers (O)						
to industrial market (P)						

<u>RECONCILIATION OF CHANNELS</u>.--Please ensure that the quantities reported for channels of distribution (i.e., lines M through P) in each time period equal the quantity reported for U.S shipments (i.e., lines D, F, and H) in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

		Calendar year	January-March		
Reconciliation item	2019	2020	2021	2021	2022
M + N + O + P - D - F - H = zero					
("0"), if not revise.	0	0	0	0	0

II-6. <u>INTEGRATED Producers' chlorinated isos operations: U.S. shipments by type</u>.--Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) by product type in 2021.

Quantity (in short tons)				
Calendar year				
Item	2021			
U.S. shipments of— Granular/powder chlorinated isos: Quantity (Q)				
Value (R)				
Tableted chlorinated isos: Quantity (S)				
Value (T)				

<u>RECONCILIATION OF U.S. SHIPMENTS BY TYPE</u>.--Please ensure that the quantities and values reported for U.S. shipments by type (i.e., lines Q through T) in 2021 equal the quantity and value reported for U.S shipments (i.e., lines D through I) in 2021. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

	Calendar year
Reconciliation item	2021
Quantity: $Q + S - D - F - H = zero$ ("0"), if not revise.	0
Value : $R + T - E - G - I = zero$ ("0"), if not revise.	0

II-7. <u>INTEGRATED Producers' chlorinated isos operations: Employment data</u>.--Report your firm's employment-related data related to the production of chlorinated isos and provide an explanation for any trends in these data.

"Production and Related Workers" (PRWs) includes working supervisors and all nonsupervisory workers (including group leaders and trainees) engaged in fabricating, processing, assembling, inspecting, receiving, storage, handling, packing, warehousing, shipping, trucking, hauling, maintenance, repair, janitorial and guard services, product development, auxiliary production for plant's own use (e.g., power plant), recordkeeping, and other services closely associated with the above production operations.

Average number employed may be computed by adding the number of employees, both full time and part time, for the 12 pay periods ending closest to the 15th of the month and divide that total by 12.

For the January to March periods, calculate similarly and divide by 3. If your firm had the same number of PRWs in all calendar year and had not experienced any changes in PRWs in the most recent interim period, you would have the same number of PRWs for the interim periods, regardless of whether the interim periods are Jan-Mar (Q1), Jan-June (Q1+Q2), or Jan-Sept (Q1+Q2+Q3)."

"Hours worked" includes time paid for sick leave, holidays, and vacation time. Include overtime hours actually worked; do not convert overtime pay to its equivalent in straight time hours.

"Wages paid" – Total wages paid before deductions of any kind (e.g., withholding taxes, old-age and unemployment insurance, group insurance, union dues, bonds, etc.). Include wages paid directly by your firm for overtime, holidays, vacations, and sick leave.

	Calendar year			January-March	
Item	2019 2020 2021			2021	2022
Employment data:					
Average number of PRWs (<i>number</i>)					
Hours worked by PRWs (1,000 hours)					
Wages paid to PRWs (\$1,000)					

Explanation of trends:		

I-8.	<u>INTEGRATED chlorinated isos operations: Transfers to related firms.</u> —If your firm reported transfers to related firms in question II-4, please identify the firm(s) and indicate the nature of
	the relationship between your firm and the related firms (e.g., joint venture, wholly owned subsidiary), whether the transfers were priced at market value or by a non-market formula, whether your firm retained marketing rights to all transfers, and whether the related firms also processed inputs from sources other than your firm.

Tableters' chlorinated isos operations

II-9. NON-TOLL Tableters' chlorinated isos operations: Production, shipment, and inventory data.-Report your firm's production capacity, production, shipments, and inventories related to non-toll tableting of purchased/imported granular/powder chlorinated isos in its U.S. establishment(s) during the specified periods. Do not report any toll production that your firm performs for other firms in this question (report these data in question II-12 of the questionnaire).

"Tableted chlorinated isos" or "tablets" -- Multi-function tablets and sticks made from trichlor or dichlor. Some tablets may contain additives including algaecides, clarifiers, or other materials.

"Average production capacity" or "capacity" – The level of production that your establishment(s) could reasonably have expected to attain during the specified periods. Assume normal operating conditions (i.e., using equipment and machinery in place and ready to operate; normal operating levels (hours per week/weeks per year) and time for downtime, maintenance, repair, and cleanup; and a typical or representative product mix).

"Production" – All production in your U.S. establishment(s), including production consumed internally within your firm and production for another firm under a toll agreement.

"Commercial U.S. shipments" – Shipments made within the United States as a result of an arm's length commercial transaction in the ordinary course of business. Report <u>net values</u> (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods) in U.S. dollars, f.o.b. your point of shipment.

"Internal consumption" – Product consumed internally by your firm. Such transactions are valued at fair market value.

"Transfers to related firms" – Shipments made to related firms. Such transactions are valued at fair market value.

"Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.

"Export shipments" – Shipments to destinations outside the United States, including shipments to related firms.

"Inventories" — Finished goods inventory, not raw materials or work-in-progress.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the trade data, as Commission staff may contact your firm regarding questions on the trade data. The Commission may also request that your company submit copies of the supporting documents/records (such as production and sales schedules, inventory records, etc.) used to compile these data.

II-9a. NON-TOLL Tableters' chlorinated isos operations: Production, shipment, and inventory data.— Continued.

Report your firm's production capacity, production, shipments, and inventories to the <u>non-toll</u> <u>tableting of purchased/imported granular/powder chlorinated isos</u> (including trichlor tablets, dichlor tablets, and blended tablets) in its U.S. establishment(s). Do not report data on repackaging and/or resales.

Quantity (in short tons) and value (in \$1,000)					
	Calendar year		January-March		
Item	2019	2020	2021	2021	2022
Purchases/imports of					
granular/powder chlorinated					
isos tableted by your firm:					
Quantity (A)					
Value (B)					
Average production capacity ¹ (quantity) (C)					
Beginning-of-period inventories					
(quantity) (D)					
Production/tableting of					
purchased/imported					
granular/powder chlorinated					
isos (quantity) (E)					
U.S. shipments:					
Commercial shipments:					
quantity (F)					
value (G)					
Internal consumption: ²					
quantity (H)					
value (I)					
Transfers to related firms: ²					
quantity (J)					
value (K)					
Export shipments: ³					
quantity (L)					
value (M)					
End-of-period inventories					
(quantity) (N)					
¹ The production capacity reporte	ed is based or	operating	hours per we	ek, weeks	s per year.
Please describe the methodology us					
capacity (use additional pages as neo		•	•		•
² Internal consumption and trans	fers to related	d firms must be	valued at fair m	arket value. Do	es your firr
use a different basis for valuing thes	e transactions	s, please specify	that basis (e.g.,	cost, cost plus,	etc.):
(however, provide the data above at	fair market v	alue).			
³ Identify your firm's principal ex	port markets:				

II-9a. NON-TOLL Tableters' chlorinated isos operations: Production, shipment, and inventory data.-Continued

RECONCILIATION OF SHIPMENTS, PRODUCTION, AND INVENTORY.--Generally, the data reported for the end-of-period inventories (i.e., line L) should be equal to the beginning-of-period inventories (i.e., line B), plus production (i.e., line C), less total shipments (i.e., lines D, F, H, and J). Please ensure that any differences are not due to data entry errors in completing this form, but rather reflect your firm's actual records; and, also provide explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

	Calendar year			January	-March
Item	2019	2020	2021	2021	2022
D + E - F - H - J - L - N = should equal zero ("0") or provide an explanation.1	0	0	0	0	0
¹ Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless accurate:					

II-9b. NON-TOLL Tableters' chlorinated isos operations: Historical U.S. shipment data. --Report the quantity and value of your firm's U.S. shipments (including commercial U.S. shipments, internal consumption, and transfers, but <u>not</u> including exports) of non-toll tableted chlorinated isos produced in your U.S. establishment(s) during the specified periods.

Quantity (in short tons)			
Item	2016	2017	2018
U.S. shipments:			
Quantity			
Value			

II-10. NON-TOLL Tableters' chlorinated isos operations: Channels of distribution. -- Report your firm's U.S. shipments (i.e. inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) by channel of distribution.

Quantity (in short tons)					
		Calendar year		January	_/ -March
Item	2019	2020	2021	2021	2022
Channels of distribution: U.S. shipments— to distributors (O)					
to repackers/tableters (P)					
to retailers (Q)					
to industrial market (R)					

<u>RECONCILIATION OF CHANNELS</u>.--Please ensure that the quantities reported for channels of distribution (i.e., lines O through R) in each time period equal the quantity reported for U.S shipments (i.e., lines F, H, and J) in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

	Calendar year			January	-March
Reconciliation item	2019	2020	2021	2021	2022
O + P + Q + R - F - H - J = zero					
("0"), if not revise.	0	0	0	0	0

II-11. NON-TOLL Tableters' chlorinated isos operations: Related firms.--If your firm reported transfers to related firms in question II-9, please identify the firm(s) and indicate the nature of the relationship between your firm and the related firms (e.g., joint venture, wholly owned subsidiary), whether the transfers were priced at market value or by a non-market formula, whether your firm retained marketing rights to all transfers, and whether the related firms also processed inputs from sources other than your firm.

II-12. <u>TOLL Tableters: Toll production of chlorinated isos.</u>--For the tolling operations of your U.S. establishment(s), report the information requested below. Supply all data requested on a calendar-year basis.

"Toll agreement"--Agreement between two firms whereby the first firm ("tollee") furnishes the raw materials and the second firm ("toller") uses the raw materials to produce a product that it then returns to the first firm with a charge for processing costs, overhead, etc.

"Average tableting operations capacity" or "capacity" – The level of tableting operations that your establishment(s) could reasonably have expected to attain during the specified periods. Assume normal operating conditions (i.e., using equipment and machinery in place and ready to operate; normal operating levels (hours per week/weeks per year) and time for downtime, maintenance, repair, and cleanup; and a typical or representative product mix).

"Production" – All production in your U.S. establishment(s) related to the tableting operations of granular/powder chlorinated isos on behalf of your customers ("tollee").

Quantity (in short tons) and value (in \$1,000)					
		Calendar year		January	_/ -March
Item	2019	2020	2021	2021	2022
Average production capacity ¹ (quantity) (A)					
Production (quantity) (B)					
Shipments: ²³ For the account of <u>U.S. producers</u> ⁴ (quantity) (C)					
(value) (D)					
For the account of <u>U.S. importers</u> ⁵ (quantity) (E)					
(value) (F)					
For the account of <u>other customers</u> ⁶ (quantity) (G)					
(value) (H)					
 ¹ The production capacity reported is bathe methodology used to calculate product ² Report your firm's shipments of chlorin refers to the amount of chlorinated isos cor ³ Less discounts, returns, allowances, and ⁴ Please identify the U.S. producers for w ⁵ Please identify the U.S. importers for w ⁶ Please identify the other customers for 	ion capacity, and ated isos which inverted, and valued prepaid freight whom your firm phom your firm phom your firm phom your firm phom	l explain any cha t converted und ie refers to your rovided these to rovided these to	nges in reported er a toll agreeme firm's fee for its olling services:	capacity ent with another services	

II-13. NON-TOLL AND TOLL Tableters' chlorinated isos operations: Employment data.--Report your firm's employment-related data related to the production of chlorinated isos and provide an explanation for any trends in these data.

"Production and Related Workers" (PRWs) includes working supervisors and all nonsupervisory workers (including group leaders and trainees) engaged in fabricating, processing, assembling, inspecting, receiving, storage, handling, packing, warehousing, shipping, trucking, hauling, maintenance, repair, janitorial and guard services, product development, auxiliary production for plant's own use (e.g., power plant), recordkeeping, and other services closely associated with the above production operations.

Average number employed may be computed by adding the number of employees, both full time and part time, for the 12 pay periods ending closest to the 15th of the month and divide that total by 12.

For the January to March periods, calculate similarly and divide by 3. If your firm had the same number of PRWs in all calendar year and had not experienced any changes in PRWs in the most recent interim period, you would have the same number of PRWs for the interim periods, regardless of whether the interim periods are Jan-Mar (Q1), Jan-June (Q1+Q2), or Jan-Sept (Q1+Q2+Q3)."

"Hours worked" includes time paid for sick leave, holidays, and vacation time. Include overtime hours actually worked; do not convert overtime pay to its equivalent in straight time hours.

"Wages paid" – Total wages paid before deductions of any kind (e.g., withholding taxes, old-age and unemployment insurance, group insurance, union dues, bonds, etc.). Include wages paid directly by your firm for overtime, holidays, vacations, and sick leave.

		Calendar year			_/ -March
Item	2019	2020	2021	2021	2022
Employment data:					
Average number of PRWs (number)					
Hours worked by PRWs (1,000 hours)					
Wages paid to PRWs (\$1,000)					

Explanati	ion of trends:			

II-14.	<u>Purchases</u> Has your firm purchased granular/powder or tableted chlorinated isos produced in
	the United States or in other countries since January 1, 2016? (Do not include imports for which
	your firm was the importer of record. These should be reported in an importer questionnaire).

"Purchase" – A transaction to buy product from a U.S. corporate entity such as another U.S. producer, a U.S. distributor, or a U.S. firm that has directly imported the product.

"Import" —A transaction to buy from a foreign supplier where your firm is the importer of record.

No	If yes Report such purchases in the table below and explain the reasons for your firms' purchases:

Note: If your firm served as the importer of record for any purchases from foreign suppliers, either for your own account or as a service for another entity, those purchases are to be considered "imports" not "purchases" and **should not** be included in the table below

		Quantity (in sho	ort tons)		
	Calendar year			January-March	
Item	2019	2020	2021	2021	2022
Purchases from U.S. importers ¹ of					
chlorinated isos from— China					
Spain					
Subject, subtotal	0	0	0	0	0
All other sources					
Purchases from domestic producers ²					
Purchases from other sources ³					
¹ Please list the name of suppliers differ by source, ² Please list the name of ³ Please list the name of	please identify the of the U.S. produce	e source for each l er(s) from which y	isted supplier: our firm purchase	 d this product:	•

II-15. Purchases of imports from subject sources. -- If your firm reported purchases from U.S. importers of chlorinated isos from China and/or Spain at any time since January 1, 2016, report those purchases by the individual importer of record and subject source.

Purchases of subject imports

		Quar	ntity (<i>in short to</i>	ons)		
Importer of	Subject		Calendar year		January-March	
record	source	2019	2020	2021	2021	2022
Subject	subtotal	0	0	0	0	0

II-15. Purchases of imports from subject sources.—Continued.

RECONCILIATION OF PURCHASES FROM SUBJECT SOURCES.--Please ensure that the quantities reported for your firms purchases of imports from subject sources reported in this question (i.e., "total purchases of imports from subject sources") in each time period equal the quantity reported for your firm's purchases from subject sources in each time period in the previous question. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

	Calendar year			January-March	
Reconciliation	2019	2020	2021	2021	2022
Purchases from subject					
sources in this table –					
purchases from subject					
sources in previous					
table = zero ("0"), if not					
revise.	0	0	0	0	0

II-16. <u>Direct imports.</u>--Since January 1, 2016, has your firm imported chlorinated isos?

"Importer" – The person or firm primarily liable for the payment of any duties on the merchandise, or an authorized agent acting on his behalf. The importer may be the consignee, or the importer of record.

No	Yes	
		If yes <u>COMPLETE AND RETURN A U.S. IMPORTERS' QUESTIONNAIRE</u>

II-17. <u>Toll production</u>.--Since January 1, 2016, has your firm been involved in a toll agreement regarding the production of chlorinated isos?

"Toll agreement"--Agreement between two firms whereby the first firm furnishes the raw materials and the second firm uses the raw materials to produce a product that it then returns to the first firm with a charge for processing costs, overhead, etc.

No	Yes	If yes Please describe the toll arrangement(s) and name the firm(s) involved.

II-18.	Foreign	trade	zones
--------	---------	-------	-------

(a) <u>Firm's FTZ operations</u>.--Does your firm produce chlorinated isos in and/or admit chlorinated isos into a foreign trade zone (FTZ)?

"Foreign trade zone" is a designated location in the United States where firms utilize special procedures that allow delayed or reduced customs duty payments on foreign merchandise. A foreign trade zone must be designated as such pursuant to the rules and procedures set forth in the Foreign-Trade Zones Act.

No	If yes Describe the nature of your firms operations in FTZs and identify the specific FTZ site(s).

(b) Other firms' FTZ operations.--To your knowledge, do any firms in the United States import chlorinated isos into a foreign trade zone (FTZ) for use in distribution of chlorinated isos and/or the production of downstream articles?

No	Yes	If yesIdentify the firms and the FTZs.

For questions II-19 and II-20, if your response differs for particular orders, please indicate and explain the particular effect of imposition and/or revocation of specific orders.

II-19.	<u>Effect of order(s).</u> Describe the significance of the existing antidumping duty orders covering imports of chlorinated isos from China and/or Spain in terms of its effect on your firm's production capacity, production, U.S. shipments, inventories, purchases, employment, revenues, costs, profits, cash flow, capital expenditures, research and development expenditures, and asset values. You may wish to compare your firm's operations before and after the imposition of the order(s).						
II-20.	operations of inventories, research and	or organizat purchases, d developm isos in the f	tionWould your firm anticipate any changes in the character of its ion, including its production capacity, production, U.S. shipments, employment, revenues, costs, profits, cash flow, capital expenditures, ent expenditures, or asset values relating to the production of uture if the antidumping duty orders on chlorinated isos from China e revoked?				
	No	Yes	If yes, supply details as to the time, nature, and significance of such changes and provide underlying assumptions, along with relevant portions of business plans or other supporting documentations that address this issue.				
II-21.	Other explanations:If your firm would like to explain further a response to a question in Part II for which a narrative box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section, including but not limited to technical issues with the MS Word questionnaire.						

PART III.--FINANCIAL INFORMATION

Address questions on t	this part of the o	questionnaire to Joanna Lo	(202-205-1888, <u>J</u>	oanna.Lo@usitc.gov).
------------------------	--------------------	----------------------------	-------------------------	----------------------

Commission staff may contact that individual regarding the confidential information subtin Part III.								
	Name							
	Title							
	Email							
	Telepl	none						
2.	Accou	nting sys	temBriefly describe your firm's financial accounting system.					
	A.		does your firm's fiscal year end (month and day)? firm's fiscal year changed during the data-collection period, explain below:					
			Please note that we are requesting that firms report their financial data on a dar year basis.					
	B.1.		be the lowest level of operations (e.g., plant, division, company-wide) for which all statements are prepared that include chlorinated isos:					
	2.	Does ye	our firm prepare profit/loss statements for chlorinated isos:					
	3.	annual Auc	ten did your firm (or parent company) prepare financial statements (including reports, 10Ks)? Please check relevant items below. Sited, unaudited, annual reports, 10Ks, 10 Qs, 10Kh, 10 Qs, 10Kh, 10					
	4.	Accour	ating basis: U.S. GAAP, IFRS, cash, tax, or other chensive basis of accounting (specify)					
		used in regardii submit (profit-a	Is requested in Part I of this questionnaire, please keep all supporting documents/records the preparation of the financial data, as Commission staff may contact your firming questions on the financial data. The Commission may also request that your company copies of the supporting documents/records (financial statements, including internal nd-loss statements for the division or product group that includes chlorinated isos, as well fic statements and worksheets) used to compile these data.					
3.	cost, j	<u>Cost accounting system</u> Briefly describe your firm's cost accounting system (e.g., standard cost, job order cost, <i>etc.</i>). If your firm uses standard cost, how often does your firm review variances from standard cost (e.g. monthly, yearly)?						

U.S. Producers' Questionnaire - Chlorinated Isos (Third Review) III-4. Allocation basis. -- Briefly describe your firm's allocation basis, if any, for COGS, SG&A, and interest expense and other income and expenses. Please also describe the method and types of documents/records used to compile your financial data. III-5. Product listing.--Please list the products your firm produces in the facilities in which it produces chlorinated isos, and provide the share of net sales accounted for by these products in 2021. Share of sales in 2021 **Products** Granulated/powder chlorinated isos % Tableted chlorinated isos % % % % III-6. Does your firm purchase inputs (raw materials, labor, energy, or any services) used in the production of chlorinated isos from any related suppliers (e.g., inclusive of transactions between related firms, divisions and/or other components within the same company)?

No--Continue to question III-8.

Yes--Continue to question III-7a.

110	Draducars'	Questionnaire -	Chlarinatad	Icos /Third	Daviand
U.S.	Producers	Questionnaire -	- Chiorinated	isos i i nira	Keviewi

III-7a.	<u>Inputs from related suppliers</u> Please identify the inputs used in the production of chlorinated
	isos that your firm purchases from related suppliers and that are reflected in question III-9a
	(integrated producer), III-10a (independent tableter), and/or III-10b (toller). For "Share of total
	COGS" please report this information by relevant input in calendar year 2021. For "Input
	valuation" please describe the basis, as recorded in the company's own accounting system, of
	the purchase cost from the related supplier; e.g., the related supplier's actual cost, cost plus,
	negotiated transfer price to approximate fair market value.

Input	Related supplier	Share of total COGS in 2021	
Input valuation method used:			

III-7b. Inputs from related suppliers at cost.--Please confirm that the inputs purchased from related suppliers, as identified in III-7a, were reported in III-9a (integrated producer), III-10a (independent tableter), and/or III-10b (toller) in a manner consistent with your firm's accounting books and records.

Yes	No	If noIn the space below, please report the valuation basis of inputs purchased from related suppliers as reported in question(s) III-9a, III-10a, and/or III-10b:

III-8. <u>Nature of chlorinated isos operations</u>.--Please check the appropriate box to indicate the nature of the financial data provided in this section of the questionnaire.

INTEGRATED PRODUCER (production of granular/powder and tableted forms of chlorinated isos)Continue to question III-9a and skip questions III-10a and III-10b.
INDEPENDENT TABLETER (tableting of purchased and/or imported granular/powder chlorinated isos for your own customers)Proceed directly to question III-10a (skip questions III-9a, III-9b, and III-10b).
TOLLER OF TABLETS ONLY (also referred to as "contract tableter")Proceed directly to question III-10b (skip questions III-9a, III-9b, and III-10a).
BOTH an independent tableter and a tollerProceed to question III-10a (skip questions III-9a and III-9b), complete both questions III-10a and III-10b, and allocate financial data for each type of operation You must allocate revenues and costs separately for your independent tableting (III-10a) and tolling (III-10b) operations, as appropriate.

III-9a. <u>INTEGRATED PRODUCER: Operations on chlorinated isos</u>.--Report the revenue and related cost information requested below on the integrated chlorinated isos operations of your firm's U.S. establishment(s), inclusive of granular/powder and tablets produced by your firm. If your firm is a tollee, report the cost of tolling services in the appropriate row below. Note that internal consumption and transfers to related firms must be valued at fair market value.

Quantity (in short t			1		
	C	alendar year		January-	March
ltem	2019	2020	2021	2021	2022
Net sales quantities: ¹ Commercial sales ("CS")					
Internal consumption ("IC")					
Transfers to related firms ("Transfers")					
Total net sales quantities	0	0	0	0	O
Net sales values: ¹ Commercial sales					
Internal consumption					
Transfers to related firms					
Total net sales values	0	0	0	0	0
Cost of goods sold (COGS): ² Urea ³					
Caustic soda ³					
All other raw materials (e.g., chlorine) ³					
Total raw materials	0	0	0	0	0
Cost of tolling services ⁴					
Direct labor					
Energy costs					
Other factory costs					
Total COGS	0	0	0	0	C
Gross profit or (loss)	0	0	0	0	0
Selling, general, and administrative ("SG&A") expenses					
Operating income (loss)	0	0	0	0	0
Other expenses and income: Interest expense					
All other expense items					
All other income items					
Net income or (loss) before income taxes	0	0	0	0	0
Depreciation/amortization included above					
11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					

¹ Include only sales (whether <u>domestic or export</u>) and costs related to your <u>U.S. manufacturing operations</u>. Net sales should be reported less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities and values reported in Part II of this questionnaire.

Note: The table above contains calculations that will appear when you have entered data in the MS Word form fields.

² COGS (whether for domestic or export sales) should include costs associated with CS, IC, and Transfers.

³ Include any raw material costs associated with the production of these items within the relevant category and list these "all other raw materials":

⁴ Costs of tolling services should include fees paid to toll processors and costs associated with moving product to the processing facility.

III-9b. <u>INTEGRATED PRODUCER: Net sales, by product form.</u>--Please report your firm's total net sales (as reported in III-9a), by the form of chlorinated isos sold to your customers.

	Calendar year			January-March	
Item	2019	2020	2021	2021	2022
	Q	uantity (in sh	ort tons); val	ue (in \$1,000)	
Total net sales of chlorinated isos.— Granular/power Quantity					
Value					
Tablets Quantity					
Value					

<u>RECONCILIATION OF TOTAL NET SALES BY FORM.</u>--Please ensure that the quantities and values reported for total net sales, by from (granular/powder or tablets), in each time period equal the data reported for total net sales in table III-9a. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

	Calendar year			January-March		
Reconciliation	2019	2020	2021	2021	2022	
Quantity: Quantity of granular/powder + tableted chlorinated isos – total net sales quantity (from question III-9a) = zero ("0").	0	0	0	0	0	
Value: Value of granular/powder + tableted chlorinated isos – total net sales quantity (from question III-9a) = zero ("0").	0	0	0	0	0	

III-10a. INDEPENDENT TABLETER: Tableting operations of chlorinated isos (non-toll).--Report the revenue and related cost information on your firm's non-toll tableting operations for purchased and/or imported granular/powder chlorinated isos (i.e., using granular/powder not produced in your facilities). Internal consumption and transfers to related firms must be valued at fair market value. Do not report any data if your firm only provides repackaging of chlorinated isos.

<u>Note</u>: If your firm operates as both an independent tableter and as a toller/contract tableter, **you must allocate revenues and costs** between your firm's tablets sold to your own customers and those for your tollee(s). Report the revenue and costs of your non-toll tableting data below.

Quantity (in short	tons) and value	(in \$1,000)			
	(Calendar year		January-	-March
Item	2019	2020	2021	2021	2022
Net sales quantities:¹ Commercial sales ("CS")					
Internal consumption ("IC")					
Transfers to related firms ("Transfers")					
Total net sales quantities	0	0	0	0	0
Net sales values: ¹ Commercial sales					
Internal consumption					
Transfers to related firms					
Total net sales values	0	0	0	0	0
Cost of goods sold (COGS):2 Granular/powder chlorinated isos from domestic producers					
Granular/powder chlorinated isos from China					
Granular/powder chlorinated isos from Spain					
Granular/powder chlorinated isos from all other sources					
Total cost of granular/powder chlorinated isos	0	0	0	0	0
Other raw material costs ³					
Direct labor					
Other factory costs					
Total COGS	0	0	0	0	0
Gross profit or (loss)	0	0	0	0	0
SG&A expenses					
Operating income (loss)	0	0	0	0	0
Other expenses and income: Interest expense					
All other expense items					
All other income items					
Net income or (loss) before income taxes	0	0	0	0	0
Depreciation/amortization included above					

¹ Include only sales (whether <u>domestic or export</u>) and costs related to your <u>U.S. manufacturing operations of tableted and non-tolled cholorinated isos</u>. Net sales should be reported less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities and values reported in Part II of this questionnaire.

Note: The table above contains calculations that will appear when you have entered data in the MS Word form fields.

² COGS (whether for domestic or export sales) should include costs associated with CS, IC, and Transfers.

³ List these "other raw materails":

III-10b. <u>TOLLER/CONTRACT TABLETER: Toll-processing operations of tableted chlorinated isos</u>.--Report the revenue and related cost information requested below on the tolling operations of your firm's U.S. establishment(s).¹ Report operations for all tollees combined. If your firm provides packaging <u>in addition</u> to tableting, the revenue and cost information for those activities should be included. Do not report any data if your firm only provides repackaging of chlorinated isos.

<u>Note</u>: If your firm also completed data in III-10a above on your non-toll tableting operations, you **must allocate costs for the tolling portion** of your tableting in the table below.

Quantity (i	n short tons) a	and value (in	\$1,000)		
	Calendar year			January	-March
Item	2019 2020		2021	2021	2022
Net quantity tolled					
Net tolling revenue					
Cost of tolling services Raw materials not supplied by tollee ²					
Direct labor					
Other factory costs					
Total cost of tolling services	0	0	0	0	0
Gross profit or (loss)	0	0	0	0	0
General and administrative expenses					
Operating income (loss)	0	0	0	0	0

¹ Include only tolling revenue (whether domestic or exports) and costs related to your <u>U.S. tableting</u> operations as a toller.

Note: The table above contains calculations that will appear when you have entered data in the MS Word form fields.

² List these "other raw materails":

III-11a. Nonrecurring items (charges and gains) included in the subject product financial results.--For each annual and interim period for which financial results are reported in questions III-9a, III-10a, and/or III-10b. please specify all material (significant) nonrecurring items (charges and gains) in the schedule below, the specific question (i.e., questions III-9a, III-10a, and/or III-10b) and line item where the nonrecurring items are included, a brief description of the relevant nonrecurring items, and the associated values (in \$1,000), as reflected in questions III-9a, III-10a, and/or III-10b. Allocate nonrecurring item(s) as appropriate, e.g., if an aggregate nonrecurring item has been allocated to question III-9a, only the allocated value amount included in question III-9a should be reported in the schedule below.

Note: The Commission's objective here is to gather information only on material (significant) nonrecurring items which impacted the reported financial results of the subject product in questions III-9a, III-10a, and/or III-10b.

		Calendar year			-March		
	2019 2020 2021				2022		
Item		Value (<i>\$1,000</i>)					
Nonrecurring item 1							
Nonrecurring item 2							
Nonrecurring item 3							
Nonrecurring item 4							
Nonrecurring item 5							

Nonrecurring item: In this table please provide a brief description of each nonrecurring item reported above and indicate the specific line item in questions III-9a, III-10a, and/or III-10b where the nonrecurring item is classified.

	Description of the nonrecurring item	Indicate in which question this item is included (III-9a, III-10a, and/or III-10b) and in which line item (e.g., "other factory costs", "all other expenses", etc.)
Nonrecurring item 1		
Nonrecurring item 2		
Nonrecurring item 3		
Nonrecurring item 4		
Nonrecurring item 5		

III-11b.	Classification of identified nonrecurring items (charges and gains) in the accounting books and
	records of the companyIf non-recurring items were reported in questions III-9a, III-10a,
	and/or III-10b, please identify where your company recorded these items in your accounting
	books and records in the normal course of business; i.e., just as responses to question III-11a
	identify where these items are reported in questions III-9a, III-10a, and/or III-10b.

1		

115	Producers'	Questionnaire -	Chlorinated	Isns (Third	Roviow
U.S.	FIUUUUCEIS	Ouesilonnalie –	Ciliorniateu	1505 t i i i i u	neview

III-12a. <u>Asset values</u>.--Report the <u>total</u> assets (i.e., both current and long-term assets) associated with the production, warehousing, and sale of chlorinated isos. If your firm does not maintain some or all of the specific asset information necessary to calculate total assets for chlorinated isos in the normal course of business, please estimate this information based upon a method (such as production, sales, or costs) that is consistent with relevant cost allocations in questions in questions III-9a, III-10a, and/or III-10b.

Note: Total assets should reflect <u>net assets</u> (after any accumulated depreciation and allowances deducted) and should be <u>allocated to the subject products</u> if these assets are also related to other products.

Value (<i>in \$1,000</i>)			
		Calendar year	
Item	2019	2020	2021
Total assets (net)			

III-12b.	<u>Description of asset values</u> Please provide explanations if there are any substantial changes in total asset value during the period; e.g., due to write-offs, major purchases, and revaluations. Also describe the main asset categories (both current and long-term) in the above response.
III-13a.	<u>Capital expenditures and research and development ("R&D") expenses</u> Report your firm's capital expenditures and R&D expenses for chlorinated isos.
	Value (in \$1.000)

Value (in \$1,000)					
	Calendar year January-Ma		-March		
Item	2019	2020	2021	2021	2022
Capital expenditures					
R&D expenses					

III-13b.	<u>Description of reported capital expenditures</u> Please describe the nature, focus, and significance of your firm's reported capital expenditures. If no capital expenditure data were reported, please explain the reason.
III-13c.	<u>Description of reported R&D expenses</u> Please describe the nature, focus, and significance of your firm's reported R&D expenses.

III-14a. <u>INTEGRATED PRODUCER: Capital investment</u>.--Please quantify the amount of capital investments (from a greenfield investment perspective) and the amount of time necessary to recreate your firm's current production capabilities today. Include additional details as needed.

Item	Value (in \$1,000)	Time to setup (in months/years)
Chemical manufacturing machinery and equipment		
Tableting machinery and equipment		
Describe:		

III-14b. <u>TABLETERS (BOTH INDEPENDENT AND TOLLER): Capital investment</u>.--Please describe and quantify the amount of capital investments (from a greenfield investment perspective) and the amount of time necessary to recreate your firm's current production capabilities today.

Item	Value (in \$1,000)	Time to setup (in months/years)
Tableting machinery and equipment		
Describe:		

115	Droducars'	Ouestionnaire -	Chlorinated Is	os (Third Review)
U.S.	Producers	Questionnaire –	Ciliorinateu is	os i i ilii a keview

III-15.	Data consistency and reconciliation Please note that we are requesting your firm's financial
	data for questions III-9a, III-10a, III-10b, III-12a, and III-13a on a calendar year basis. Please
	confirm that your firm reported these data on a calendar-year basis:

Yes	No	If no, please explain.

Please note the quantities and values reported in questions III-9a, III-10a, and/or III-10b should reconcile with the data reported in question II-4 (including export shipments) as long as they are reported on the same calendar year basis.

RECONCILIATION OF TRADE VS FINANCIAL DATA.--Please ensure that the quantities and values reported for total shipments in Part II equal the quantities and values reported for total net sales in Part III of this questionnaire in each time period. If the calculated fields below return values other than zero (i.e., "0") and both are being reported on a calendar basis, please explain the discrepancy below.

	Ca	lendar year da	January-March		
Reconciliation	2019	2020	2021	2021	2022
INTEGRATED PRODUCERS: Reconciliation of all chlorinated	l isos total ship	ments and sale	es (II-7 and III-	ea)	
Quantity: Total shipments (from question II-7) less total net sales (from question III-9a) = zero ("0").	0	0	0	0	0
Value: Total shipments (from question II-7) less total net sales (from question III-9a) = zero ("0").	0	0	0	0	0
INDEPENDENT TABLETERS (NON-TOLL): Reconciliation of non-toll tablets total shipments and sales (II-9a and III-10a)					
Quantity: Total tablet shipments (from question II-9) less total tablet net sales from question III-10a) = zero ("0").	0	0	0	0	0
Value: Total tablet shipments (from question II-9a) less total tablet net sales (from question III-10a) = zero ("0").	0	0	0	0	0
TOLLERS: Reconciliation of tolling (II-12 and III-10b)	TOLLERS: Reconciliation of tolling (II-12 and III-10b)				
Quantity: Total tolling shipments (from question II-12) less net tolling (from question III-10b) = zero ("0").	0	0	0	0	0
Value: Total tolling shipments (from question II-12) less net tolling (from question III-10b) = zero ("0").	0	0	0	0	0

Do the cells in the table above show zero ("0")?

Yes	No	If no, please explain.

115	Droducars'	Ouestionnaire -	Chlorinated Is	os (Third Review)
U.S.	Producers	Questionnaire –	Ciliorinateu is	os i i ilii a keview

III-16.	Effects on financial performance of COVID-19Since January 1, 2020, has the COVID-19
	pandemic or have any government actions taken to contain the spread of the COVID-19 virus
	affected the financial performance of your firm's operations on chlorinated isos as reported in
	III-9a, III-10a, and/or III-10b? In your response, please include the duration and timing of any
	impacts as they relate to your firm's financial performance.

No	Yes	If yes, please describe these effects.	

III-17.	Other explanationsIf your firm would like to further explain a response to a question in Part II for which a narrative box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section, including but not limited to technical issues with the MS Word questionnaire.

PART IV.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from Kamron Daugherty (202-205-3168, Kamron.Daugherty@usitc.gov).

IV-1. <u>Contact information</u>.--Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in Part IV.

Name	
Title	
Email	
Telephone	

PRICE DATA

- IV-2. This question requests quarterly quantity and value data for your firm's commercial shipments to unrelated U.S. customers of the following products produced by your firm.
 - <u>Product 1</u>.-- Granular trichloroisocyanuric acid with approximately 90 percent available chlorine content (similar to ACL®90 or CDB®), sold in bulk packages equal to or greater than 1,000 pounds and less than or equal to 2,205 pounds.
 - <u>Product 2.--</u> Granular sodium dichloroisocyanuric (dihydrate) with approximately 56 percent available chlorine content (similar to ACL®56 or CDB®56), sold in bulk packages equal to or greater than 1,000 pounds and less than or equal to 2,205 pounds, sold for repackaging for pool treatment use.
 - <u>Product 3a.--</u> 3-inch or comparable trichlor tablets, with tablet volume of 6 to 8 ounces, in 35-55 pound containers for tableting conducted in the United States with U.S.-produced chlorinated isos
 - <u>Product 3b.</u>-- 3-inch or comparable trichlor tablets, with tablet volume of 6 to 8 ounces, in 35-55 pound containers for tableting conducted in the United States with imported chlorinated isos.
 - <u>Product 4a.</u>-- Blended 3-inch or comparable tablets, with tablet volume of 6 to 8 ounces, with approximately 85 to 90 percent available chlorine content, in 24-26 pound containers for tableting conducted in the United States with U.S. produced chlorinated isos.
 - <u>Product 4b.--</u> Blended 3-inch or comparable tablets, with tablet volume of 6 to 8 ounces, with approximately 85 to 90 percent available chlorine content, in 24-26 pound containers for tableting conducted in the United States with imported chlorinated isos.

Please note that values should be <u>f.o.b.</u>, <u>U.S.</u> <u>point of shipment</u> and should not include U.S.-inland transportation costs. Values should reflect the *final net* amount paid to your firm (i.e., should be net of all deductions for discounts or rebates).

c	During January 2019 -March 2022, did your firm produce and sell to unrelated U.S. sustomers any of the above listed products (or any products that were competitive with hese products)?
	YesPlease complete the following pricing data tables as appropriate.
	NoSkip to question IV-3.

IV-2b. <u>Price data</u>.--Report below the quarterly price data¹ for pricing products² produced and sold by your firm.

Report data in actual pounds (not short tons) and actual dollars (not 1,000s).

(Quanti	ty in pounas, v	alue <i>in dollars</i>)			
Product 1		Product 2		Product 3a	
Quantity	Value	Quantity	Value	Quantity	Value
	Quantity	Product 1 Quantity Value	Quantity Value Quantity	Product 1 Quantity Value Quantity Value Value	Product 1 Product 2 Product

¹ Net values (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods), f.o.b. your firm's U.S. point of shipment. Please subtract any discounts, rebates, and returns from the quarter in which the sale occurred.

NoteIf your firm's product does not exactly meet the product specifications but is competitive with the specified produ	ct,
provide a description of the product. Also, please explain any anomalies in your firm's reported pricing data.	

, , , , , , , , , , , , , , , , , , ,
Product 1:
Product 2:
Product 3a:

² Pricing product definitions are provided on the first page of Part IV.

IV-2b. **Price data.—Continued**

(Quantity in pounds, value in dollars)							
	Produc	t 3b	Produc	t 4a	Product	t 4b	
Period of shipment	Quantity	Value	Quantity	Value	Quantity	Value	
2019:							
January-March							
April-June							
July-September							
October-December							
2020:							
January-March							
April-June							
July-September							
October-December							
2021:							
January-March							
April-June							
July-September							
October-December							
2022:							
January-March							
¹ Net values (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods), f.o.b. your firm's U.S. point of shipment. Please subtract any discounts, rebates, and returns from the quarter in which the sale occurred. ² Pricing product definitions are provided on the first page of Part IV.							
Note. If your firm's product does not exactly meet the product specifications but is competitive with the specified product, provide a description of the product. Also, please explain any anomalies in your firm's reported pricing data.							
Product 3b:							
Product 4a:							
Product 4b:							

IV-2 c. Price data checklist.--Please check that the pricing data in question IV-2(a) has been correctly reported.

Are the price data reported above:	√ if Yes
In actual dollars (not \$1,000) and pounds?	
F.o.b. U.S. point of shipment (i.e., does not include U.S. transport costs)?	
Net of all discounts and rebates?	
Have discounts, rebates, and returns been credited to the quarter in which the sale occurred?	
Quantities do not exceed commercial shipments reported in part II in each year?	
Explanation(s) for any boxes not checked:	

115	Producers'	Questionnaire -	- Chlorinated	Isns (Third	Review
u.s.	Producers	Questionnaire -	- Ciliorinateu	1505 t i i i i u	Review

Delivered

F.o.b.

IV-2d.	Pricing data methodologyPlease describe the method and the kinds of documents/records
	that were used to compile your price data.

of the suppoi	•			ay also request that your company submi sales journal, invoices, etc.) used to compi	
data.					
Price setting	How does v	our firm de	termine t	he prices that it charges for sales of chlor	
	l that apply)?		termine	The prices that it charges for sales of chior	
Transaction	ı	Set			
by	by				
transaction	Contracts	lists Other		If other, describe	
		<u>'</u>	"		
Discount pol	i cy Please in	dicate and	describe	your firm's discount policies (<i>check all the</i>	
	Ammund			T	
		No			
	total	140			
Ouantity	total volume	discount			
Quantity discounts	total volume discounts	discount policy	Other	Describe	
<u>Discount pol</u>	Annual	ndicate and	describe	your firm's discount policies (<i>check all</i>	
Quantity		discount			
•	volume		Other	Describe	

If f.o.b., specify point

IV-6. <u>Contract versus spot.</u>--Approximately what share of your firm's sales of its U.S.-produced chlorinated isos in 2021 was on a (1) short-term contract basis, (2) annual contract basis, (3) long-term contract basis, and (4) spot sales basis?

	Short-term contracts (multiple deliveries for less than 12 months)	Annual contracts (multiple deliveries for 12 months)	Long-term contracts (multiple deliveries for more than 12 months)	Spot sales (for a single delivery)	Total (shoul sum t 100.0%	ld o
Share of 2021 sales	%	%	%	%	0.0	%

IV-7. <u>Contract provisions.</u>— Please fill out the table regarding your firm's typical sales contracts for U.S.-produced chlorinated isos (or check "not applicable" if your firm does not sell on a short-term, annual and/or long-term contract basis).

Typical sales contract provisions	ltem	Short-term contracts (multiple deliveries for less than 12 months)	Annual contracts (multiple deliveries for 12 months)	Long-term contracts (multiple deliveries for more than 12 months)		
Average contract duration	No. of days		365			
Price renegotiation	Yes					
(during contract period)	No					
	Quantity					
Fixed quantity and/or price	Price					
ana, or price	Both					
Indexed to raw	Yes					
material costs ¹	No					
Not applicab	le					
¹ Please identify the indexes used:						

				_	
110	D/	Questionnaire –	Cla I = = 4 = -1	1 /Tl-:	D!
	Dradiicarc	I III DETIANNATIO 🗕	INIORINATOR	ICAC I I NIPA	ROMBIN

IV-8. <u>Lead times.--</u>What is the typical lead time between a customer's order and the date of delivery for your firm's sales of its U.S.-produced chlorinated isos?

Source	Share of 2021 sales	Lead time (average number of days)
From inventory	%	
Produced to order	%	
Total (should sum to 100.0%)	0.0 %	

IV-9.	Shipping	information

(a)	Who generally:	arranges the ti	ransportati	on to your firn	n's customers'	locations?
	Your firm	Purchaser	(check one)			

(b) Indicate the approximate percentage of your firm's sales of chlorinated isos that are delivered the following distances from your firm's production facility.

Distance from production facility	Share
Within 100 miles	%
101 to 1,000 miles	%
Over 1,000 miles	%
Total (should sum to 100.0%)	0.0 %

IV-10. <u>Geographical shipments</u>.--In which U.S. geographic market area(s) has your firm sold its U.S.-produced chlorinated isos since January 1, 2016 (check all that apply)?

Geographic area	√ if applicable
NortheastCT, ME, MA, NH, NJ, NY, PA, RI, and VT.	
MidwestIL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI.	
Southeast.—AL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV.	
Central Southwest.—AR, LA, OK, and TX.	
Mountains.–AZ, CO, ID, MT, NV, NM, UT, and WY.	
Pacific Coast.–CA, OR, and WA.	
Other.—All other markets in the United States not previously listed, including AK, HI, PR, and VI.	

U.S. Pro	U.S. Producers' Questionnaire – Chlorinated Isos (Third Review) Page 48								
IV-11.	<u>Inland transportation costs.</u> —What is the approximate percentage of the cost of U.Sproduced chlorinated isos that is accounted for by U.S. inland transportation costs? percent								
IV-12.	. <u>End uses</u> Have there been any changes in the end uses of chlorinated isos since January 1, 2016? Do you anticipate any future changes?								
	Changes in end uses	N	0	Yes	Explain				
	Changes since January 1, 2016								
	Anticipated changes								
IV-13.					ny changes in the number or types of products that can be since January 1, 2016? Do you anticipate any future changes?				
	Changes in substitutes	No	Ye	es	Explain				
	Changes since January 1, 2016								
	Anticipated changes								

IV-14. **Availability of supply.--**Has the availability of chlorinated isos in the U.S. market changed since January 1, 2016? Do you anticipate any future changes?

Availability in the U.S.			Please explain, noting the countries and reasons for the
market	No	Voc	changes.
market	No	162	changes.
Changes since January 1, 2	2016:		
U.Sproduced product			
Imports from China and/or Spain			
Imports from all other countries			
Anticipated changes:			
U.Sproduced product			
Imports from China and/or Spain			
Imports from all other countries			

IV-15. <u>Demand trends.</u>--Indicate how demand within the United States and outside of the United States (if known) for chlorinated isos has changed since January 1, 2016, and how you anticipate demand will change in the future. Explain any trends and describe the principal factors that have affected, and that you anticipate will affect, these changes in demand.

Market	Overall increase	No change	Overall decrease	Fluctuate with no clear trend	Explanation and factors				
Demand since January 1, 2016									
Within the United States									
Outside the United States									
			Anticipated	l future dema	and				
Within the United States									
Outside the United States									

115	Droducars'	Questionnaire -	Chlorinated	Isos (Third	Roviow
u.s.	Producers	Questionnaire -	Ciliorinateu	1505 (I I I I I I I	Review

IV-16.	Product changes. Have there been any significant changes in the product range, product mix, or marketing of chlorinated isos since January 1, 2016? Do you anticipate any future changes?						
	Change product product marke	range, mix, or	No	Yes		Explain	
	Changes s January 1						
	Anticipate changes	ed					
IV-17.	17. Conditions of competition(a) Is the chlorinated isos market subject to business cycles and/or other conditions of competition distinctive to chlorinated isos?						
	Check all that apply.					Please describe.	
		☐ No				Skip to question IV-18.	
	Yes-Business cycles (e.g. seasonal business)						
					inctive competition		
					iny changes in nuary 1, 2016?	the business cycles or conditions of competition for	
	No	Yes	}	If ye	s, describe.		
IV-18.	18. Supply constraints. Has your firm refused, declined, or been unable to supply chlorinated iso since January 1, 2016 (examples include placing customers on allocation or "controlled order entry," declining to accept new customers or renew existing customers, delivering less than the quantity promised, being unable to meet timely shipment commitments, etc.)?						
	No	Yes	If	yes, p	lease describ	е.	

IV-19.	Raw materials Indicate how chlorinated isos raw material prices have changed since January
	1, 2016, and how you expect they will change in the future.

Raw materials prices	Overall increase	No change	Overall decrease	Fluctuate with no clear trend	Explain, noting how raw material price changes have affected your firm's selling prices for chlorinated isos.
Changes since January 1, 2016					
Anticipated changes					

IV-20.	Impact of section 301 tariffs.—Did the imposition of tariffs on Chinese origin products under
	section 301 have an impact on the chlorinated isos market in the United States

Yes — Please indicate the impact in the table below.	No	Don't know

Factor	Overall increase	No change	Overall decrease	Fluctuate with no clear trend	Explain, noting how the imposition of tariffs under section 301 affected each factor of the chlorinated isos market in the United States.
Supply of U.S produced chlorinated isos					
Supply of chlorinated isos imported from China					
Supply of chlorinated isos imported from other countries					
Prices for chlorinated isos					
Overall U.S. demand for chlorinated isos					
Raw material costs for chlorinated isos					

IV-21.		if known	sPlease compare market prices of chlorinated isos in U.S. and non-U.S. Provide specific information as to time periods and regions for any price					
IV-22.	Market studiesPlease provide as a separate attachment to this request any studies, surveys, etc. that you are aware of that quantify and/or otherwise discuss chlorinated isos supply (including production capacity and capacity utilization) and demand in (1) the United States, (2) each of the other major producing/consuming countries, including China and/or Spain, and (3) the world as a whole. Of particular interest is such data from 2016 to the present and forecasts for the future.							
IV-23.	the U.S. i	market ar s, other safting chlo	2Describe how easily your firm can shift its sales of chlorinated isos between a laternative country markets. In your discussion, please describe any ales arrangements, or other constraints that would prevent or retard your firm rinated isos between the U.S. and alternative country markets within a 12-					
IV-24.			Are your firm's exports of chlorinated isos subject to any tariff or non-tariff n other countries?					
	No	Yes	If yes, please list the countries and describe any such barriers and any significant changes in such barriers that have occurred since January 1, 2016, or that are expected to occur in the future.					

IV-25. <u>Interchangeability</u>.--Is chlorinated isos produced in the United States and in other countries interchangeable (i.e., can they physically be used in the same applications)?

Please indicate A, F, S, N, or 0 in the table below:

- A = the products from a specified country-pair are *always* interchangeable
- F = the products are *frequently* interchangeable
- S = the products are *sometimes* interchangeable
- N = the products are *never* interchangeable
- 0 = *no familiarity* with products from a specified country-pair

Country-pair	China	Spain	Other countries
United States			
China			
Spain			

For any country-pair producing chlorinated isos that is *sometimes* or *never* interchangeable, identify the country-pair and explain the factors that limit or preclude interchangeable use:

IV-26.	Factors other than priceAre differences other than price (e.g., quality, availability,
	transportation network, product range, technical support, etc.) between chlorinated isos
	produced in the United States and in other countries a significant factor in your firm's sales of
	the products?

Please indicate A, F, S, N, or 0 in the table below:

IV-27.

IV-28.

A = such differences are *always* significant

F = such differences are *frequently* significant

S = such differences are *sometimes* significant

	differences a <i>miliarity</i> with	_	π a specified cou	untry-pair		
Country-pair	Chi	na	Spain		Other countr	ries
United States						
China						
Spain			\bigwedge			
factor in your fi	rm's sales of	chlorinated is	•	ountry-pa	frequently a signif ir and relevant fact	
changes in these including any eff 2016?	tariffs, have a ects on chlori	an impact on nated isos co	the chlorinated ist, price, supply,	isos marke and/or de	s under section 301 t in the United Sta mand, since Janual	tes,
Yes			No	С	Oon't know	
f yes, please des he timing of suc		act on cost, p	orice, supply, an	d/or dema	and, and include	
V that did not p	rovide a narra ne space provi	tive response ded below. P	box, please not lease also use th	e the ques	nse to a question i ition number and t highlight any issue	he

PART V.--PRODUCT AND INDUSTY CONSIDERATIONS

Further information on this part of the questionnaire can be obtained from Keysha Martinez (202-205-2136, Keysha.Martinez@usitc.gov).

Note: All three categories of firms conducting production-related activities in the United States should complete this section of the questionnaire:

- Integrated producers: That are reporting trade and financial data in parts II and III.
- Independent tableters: That are reporting trade and financial data in parts II and III.
- Toll tableters: That are reporting trade and financial data in part VI.

	-		ce January 1, 2016, has your firm either produced granular/powogranular/powder chlorinated isos in the United States?			
No	Yes	If yes—Please describe the nature and extent of the following items in				
		relation to your firm's production or processing operations in the United States.				
Capital investments						
Technical expertise						
Value added						
Employment						

V-3. Operations' complexity and importance.--On a scale of 1 to 5, please provide your firm's subjective opinion as to the complexity, intensity, and importance of your firm's production-related activities. 1 being minimally complex, intense or important; 5 being extremely complex, intense, and important.

1: Minimally complex, intense, and important	2	3	4	5: Extremely complex, intense, and important				
Please describe the reason for your rating below.								

HOW TO FILE YOUR QUESTIONNAIRE RESPONSE

This questionnaire is available as a "fillable" form in MS Word format on the Commission's website at:

https://usitc.gov/investigations/701731/2021/chlorinated isocyanurates china and sp ain/third review full.htm

Please do not attempt to modify the format or permissions of the questionnaire document. Please submit the completed questionnaire using one of the methods noted below. If your firm is unable to complete the MS Word questionnaire or cannot use one of the electronic methods of submission, please contact the Commission for further instructions.

• <u>Upload via Secure Drop Box</u>.—Upload the MS Word questionnaire along with a scanned copy of the signed certification page (page 1) through the Commission's secure upload facility:

Web address: https://dropbox.usitc.gov/oinv/ Pin: ISOS

• E-mail.—E-mail the MS Word questionnaire to Keysha.Martinez@usitc.gov; include a scanned copy of the signed certification page (page 1). Submitters are strongly encouraged to encrypt nonpublic documents that are electronically transmitted to the Commission to protect your sensitive information from unauthorized disclosure. The USITC secure drop-box system and the Electronic Document Information System (EDIS) use Federal Information Processing Standards (FIPS) 140-2 cryptographic algorithms to encrypt data in transit. Submitting your nonpublic documents by a means that does not use these encryption algorithms (such as by email) may subject your firm's nonpublic information to unauthorized disclosure during transmission. If you choose a non-encrypted method of electronic transmission, the Commission warns you that the risk of such possible unauthorized disclosure is assumed by you and not by the Commission.

If your firm does not produce this product, please fill out page 1, print, sign, and submit a scanned copy to the Commission.

<u>Parties to this proceeding</u>.—If your firm is a party to this proceeding, it is required to serve a copy of the completed questionnaire on parties to the proceeding that are subject to administrative protective order (see 19 CFR § 207.7). A list of such parties may be obtained from the Commission's Secretary (202-205-1802). A certificate of service must accompany the completed questionnaire you submit (see 19 CFR § 207.7). Service of the questionnaire must be made in paper form.